Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business

PHT Corporation SitePad® Used to Collect Electronic Data for Celgene’s Recently Approved OTEZLA (apremilast) Tablets


Print article Print article
© Business Wire 2014
2014-05-01 09:02:03 -

Celgene Corporation used the PHT Corporation : cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww .. SitePad ® System : cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww .. to collect primary and secondary endpoints for studies of its Otezla (apremilast) drug which the FDA approved in March 2014 to treat adults with active psoriatic arthritis (PsA).

PHT is the leading provider of technologies used to collect patient-driven eData : cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww .. for clinical research. The PHT SitePad System includes a large-screen mobile tablet for capturing study-specific clinician and patient assessments at the investigative site. Real-time access to all the data collected is available in StudyWorks™, the PHT online portal for data review and management. Using the SitePad System helps to increase the quality of the data collected, the time

to database lock and reduces monitoring time and costs.

The safety and effectiveness of Otezla, an oral inhibitor of phosphodieasterase-4 (PDE-4), were evaluated in three clinical trials involving 1,493 patients with active PsA. Patients treated with Otezla showed improvement in signs and symptoms of PsA, including tender and swollen joints and physical function, compared to placebo.

PHT President and CEO Philip Lee said, “PHT is honored to have been a part of this development program which has resulted in success for Celgene and patients suffering from PsA around the globe. The PHT team members who worked on this project are gratified both personally and professionally to be part of bringing this important new therapy to market.”


About PHT Corporation

PHT Corporation is the eClinical innovator leading the adoption of patient-driven mobile apps for better clinical research. The PHT electronic clinical outcome assessment (eCOA) system collects and reports secure real-time patient data from the latest mobile devices.
PHT scientific, regulatory and technological expertise combined with quality outcomes data enable clients to make research decisions with confidence. Sponsors and CROs have leveraged the PHT Patient Suite in 650+ trials resulting in 16+ regulatory approvals. Visit phtcorp.com : cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww .. for more information on PHT. Follow PHT on LinkedIn : cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Flin .. , Twitter : cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fbit .. , Google+ : cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fbit .. and YouTube : cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fbit .. .

" title="http://cts.businesswire.com/ct/CT?id=bwnews&sty=20140501005468r1&sid=16929&distro=ftp\"/>" target="_blank" rel="nofollow">cts.businesswire.com/ct/CT?id=bwnews&sty=20140501005468r1&am ..

Media contact:Brenda Nashawaty CommunicationsBrenda

Nashawaty, 617-688-3253 brenda@nashawaty.com : mailto:brenda@nashawaty.com


Author:
Hossam Abdel-Kader
e-mail
Web: www.pr-inside.com/
Phone: +43 1 9582319

Disclaimer: (c) 2014 Business Wire. All of the news releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com